MJH Life Sciences to Acquire the Pharmacy Benefit Management Institute
The acquisition will include PBMI’s trademarks, conference, website, education, and membership assets.
MJH Life Sciences, a medical media company based in Cranbury, NJ, and the owner of Pharmaceutical Technology and BioPharm International, announced on April 2, 2020 that it has acquired the Pharmacy Benefit Management Institute (PBMI), a Plano, TX-based provider of research and education for the pharmacy benefit market, from Pharmaceutical Strategies Group (PSG).
According to a company press release, the acquisition will include PBMI’s trademarks, conference, website, education, and membership assets. Additionally, all current and future research and analytics projects will remain with PSG under the leadership of Sharon Frazee, PhD, senior vice-president of Research and Data Innovation at PBMI.
“Credible information is critical to healthcare professionals during this global pandemic, and education about how it will impact drug benefit management is vital,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences, in the press release. “For 25 years, PBMI’s annual meeting has been a driver of change within the marketplace, and as part of our Managed Markets Network, we look forward to growing the conference to make an even bigger impact in the field of managed care.”
“After careful consideration, we have decided to give PBMI a new home where it can continue its mission and prosper for many years to come,” added Dave Borden, CEO of PSG, in the press release. “MJH Life Sciences is a global business with significant resources and experience in the area of conference management and education, and we are confident the organization will enable PBMI to further its mission and reach new heights. We look forward to continuing our relationship with PBMI and hope to see our friends, partners, and colleagues at PBMI events for many years to come.”
Source: MJH Life Sciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
